abstract |
Compositions comprising at least one TGF-β modulator for treating TGF-β mediated ocular pathologies are disclosed. Methods directed to the treatment of these pathologies, and in particular, glaucoma, ocular hypertension, PVR, secondary cataract, corneal haze and glaucoma filtration surgery bleb failure are also disclosed. |